All In Biotech

Drug Trial Radar · NCT07236944

Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care: A Randomized Controlled Non-Inferiority Multicenter Trial

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Dec 2025

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Uppsala UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Research Council
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if oral treatment with pivmecillinam is effective to treat febrile urinary tract infections in adult patients. Hospitalized patients who have received 2-4 days of intravenous antibiotic therapy for febrile urinary tract infections, and have responded to treatment, will be randomized to either pivmecillinam or standard treatment (other oral or intravenous antibiotics). The main question the study aims to answer is if oral follow-up with pivmecillinam is as effective as standard treatment. Patients will be evaluated for clinical response (resolution of fever and urinary tract symptoms) and microbiological response (no growth of bacteria in urine) 7 and 28 days after the end of treatment. Patients will also be asked about side effects. Some of the participants will also be examined for changes in the gut microbiome and drug exposures in blood and urine. Participants will: 1. Keep a patient diary to record antibiotic intake, body temperature, urinary tract symptoms, and suspected side effects until 7 days after end of treatment. 2. Participate in phone interviews 7 and 28 days after end of treatment to assess clinical response. 3. Provide urine samples 7 and 28 days after end of treatment to evaluate microbiological response. 4. A subgroup (60 patients) will provide fecal samples at five time-points over three months to assess antibiotic-induced changes in the gut microbiome. 5. A subgroup (30 patients) treated with to pivmecillinam will provide blood and urine samples to determine the pharmacokinetics of mecillinam during one dosing interval.

Conditions

  • Febrile Urinary Tract Infection

Interventions

  • PivmecillinamDrug

    Patients randomized to pivmecillinam will be provided with 400 mg tablets for 3 to 8 days of treatment, to be taken four times daily, resulting in a total treatment duration of 7 or 10 days (including the initial 2-4 days of intravenous treatment). The shorter treatment duration of 7 days will be used for female patients with no complicating factors (structural or functional urologic abnormalities, urinary tract catheterization, and diabetes mellitus). The longer treatment duration of 10 days will be used for all other patients.

  • Standard of Care (Investigator Choice)Drug

    The control group will receive standard of care antibiotic treatment at the discretion of the responsible physician and according to existing treatment guidelines, with a total treatment duration of 7 to 14 days. The following antibiotics will be considered adequate. Intravenous antibiotics: 1) Penicillins; ampicillin, piperacillin/tazobactam, 2) cephalosporins; cefotaxime, cefuroxime, ceftriaxone, 3) carbapenems; ertapenem, imipenem, meropenem, 4) monobactams; aztreonam, 5) aminoglycosides; amikacin, gentamicin, tobramycin, 6) other; fosfomycin. Oral antibiotics: 1) ciprofloxacin, 2) trimethoprim-sulfamethoxazole, 3) amoxicillin or amoxicillin/clavulanic acid provided that the isolated E. coli is determined susceptible according to the EUCAST-breakpoint for systemic infections, i.e., MIC ≤ 8 mg/l, and high dosing is used (≥750 mg amoxicillin x 3 and ≥750 mg amoxicillin/125 mg clavulanic acid x 3, respectively) and 4) tebipenem (if approved by the EMA).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical response (primary endpoint).Time frame: 7 (+/-2) days after EOT

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Haukeland University Hospital

    Haukeland, Norway · Not yet recruiting

  • Oslo University Hospital

    Oslo, Norway · Not yet recruiting

  • Södra Älvsborg Hospital

    Borås, Sweden · Not yet recruiting

  • Eskilstuna Hospital

    Eskilstuna, Sweden · Not yet recruiting

  • Sahlgrenska University Hospital

    Gothenburg, Sweden · Recruiting

  • Blekinge Hospital

    Karlskrona, Sweden · Not yet recruiting

  • Skåne University Hospital

    Lund, Sweden · Not yet recruiting

  • Örebro University Hospital

    Örebro, Sweden · Recruiting

  • Karolinska University Hospital

    Stockholm, Sweden · Not yet recruiting

  • Sundsvall Hospital

    Sundsvall, Sweden · Not yet recruiting

  • Umeå University Hospital

    Umeå, Sweden · Not yet recruiting

  • Uppsala University Hospital

    Uppsala, Sweden · Recruiting

  • Central Hospital Växjö

    Vaxjo, Sweden · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.